Immune cell therapy shows promising results in treating blood cancer.

A clinical trial has found that a revolutionary blood cancer treatment, ciltacabtagene autoleucel, which genetically modifies patient cells to fight the disease, cuts the risk of it progressing by 74%. The therapy belongs to a class of drugs known as Car-T therapies and significantly slows or stops progression of multiple myeloma in patients who have stopped responding to other treatments. Multiple myeloma is an incurable blood cancer that affects a type of white blood cell called plasma cells, found in the bone marrow. The treatment is already available to some patients in the US and parts of Europe but not yet in the UK.